Lv12
40 积分 2025-10-29 加入
P1.07.53 Aumolertinib as Adjuvant Therapy in I-III EGFRm NSCLC : Also Effective in Patients With Multiple Prognostic Risk Factors
17小时前
已关闭
P1.07.48 Furmonertinib as Adjuvant Therapy in Postoperative EGFR-Mutated Stage IB-IIA NSCLC With High-Risk Pathological Factors
19小时前
求助中
P1.07.50 Aumolertinib as Adjuvant Therapy in EGFRm Stage I-III NSCLC With High-Grade Histological Patterns: 3-Year Dfs Rate Updated
19小时前
求助中
P1.07.53 Aumolertinib as Adjuvant Therapy in I-III EGFRm NSCLC : Also Effective in Patients With Multiple Prognostic Risk Factors
19小时前
求助中
P1.07.54 The Effect of Adjuvant EGFR-TKI Therapy on the Prognosis of Pathological Stage I Invasive Lung Adenocarcinoma With Sensitive EGFR Mutation
19小时前
求助中
皖公网安备34019202002308
